SDGR
TentativeAI MemoPost-earnings T+3Schrodinger
As of 2026-08-08/Post-earnings T+3/Confidence medium
Data freshness
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Report quality notice
peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Action
—
Confidence
medium
Horizon
—
Key catalyst
Q2 ACV growth and higher drug-discovery guidance • 2026-08-05
Base target: $18 / p=1% prob
Biggest risk
The quarter included a $48.9 million other-income benefit largely tied to the Ajax acquisition, while software revenue declined and Bunsen monetization is not yet demonstrated. The deterministic prior remains negative.
Invalidation
Break below $14 or thesis failure.
What would change my mind?
ACV growth, Bunsen adoption, the BMS deployment, and collaboration economics could improve long-term platform utilization. The $418.8 million cash, cash equivalents, restricted cash, and marketable securities balance provides flexibility.
Research note
Recommendation
—
Confidence
medium
As of
2026-08-08
Base target
$18
p=1%
Bull target
$22
p=0%
Bear target
$14
p=0%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- Hosted-software transition remains an execution monitor
- Bunsen early access and Bristol Myers Squibb deployment
- ACV growth, Bunsen adoption, the BMS deployment, and collaboration economics could improve long-term platform utilization.
BearKey bullets
- Bunsen adoption, pricing, and contribution to ACV remain unproven.
- Drug-discovery revenue depends on collaboration milestones and partner execution.
- Hosted-software migration may pressure reported revenue and require sustained customer adoption.
WatchKey bullets
- Q2 ACV growth and higher drug-discovery guidance
Summary
High-level snapshot
Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
Post-earnings T+3
Base case: $18 (p=1%)
Target spread vs base: +22% / -22%
Scenario probabilities
Bull Target: $22 (p=0%)Base Target: $18 (p=1%)Bear Target: $14 (p=0%)
Commentary
The company source confirms the Q2 release, ACV growth, guidance change, Bunsen launch, and BMS agreement. The August 6 anchor was $17.81, but no clean pre-print comparison or trustworthy source attributing the market move to results was available. No post-print analyst reaction or revision signal was identified, so the tone remains moderately positive but the thesis stays monitoring-oriented.
As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
ACV growth, Bunsen adoption, the BMS deployment, and collaboration economics could improve long-term platform utilization. The $418.8 million cash, cash equivalents, restricted cash, and marketable securities balance provides flexibility.
Bear Case
The quarter included a $48.9 million other-income benefit largely tied to the Ajax acquisition, while software revenue declined and Bunsen monetization is not yet demonstrated. The deterministic prior remains negative.
Drivers
Scannable catalysts and supporting factors
- Hosted-software transition remains an execution monitor
- Bunsen early access and Bristol Myers Squibb deployment
Scenarios
Bull Target (Scenario probability)
$22 / p=0% prob
Base Target (Scenario probability)
$18 / p=1% prob
Bear Target (Scenario probability)
$14 / p=0% prob
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
Sentiment unavailable: insufficient coverage
Events
Other notable items detected
- EVENT2026-08-05Q2 ACV growth and higher drug-discovery guidanceQ2 ACV was $29.6 million, up 27% year over year, while drug-discovery revenue guidance increased to $65–75 million from $55–65 million after a $10 million Ajax-related collaboration milestone. [#SEC-8K-2026-08-05]Prob 75.00% • Move 8.00% • Priced-in 65.00%
Short-term Catalysts
Next few weeks
- Hosted-software transition remains an execution monitor2026-09-30Software revenue declined 10% year over year as the company accelerated its transition to hosted licensing; hosted revenue reached 47% of quarterly software revenue, making adoption and monetization the key near-term test. [#SEC-8K-2026-08-05]Prob 70% • Move -6% • Priced-in 50%
Long-term Catalysts
Months to a year
- Bunsen early access and Bristol Myers Squibb deployment2027-08-08Schrödinger launched early access for Bunsen and announced a strategic software agreement with Bristol Myers Squibb, creating a potential platform-adoption path, though commercial scale remains unproven. [#SEC-8K-2026-08-05]Prob 55% • Move 15% • Priced-in 55%
Risks
- Bunsen adoption, pricing, and contribution to ACV remain unproven.
- Drug-discovery revenue depends on collaboration milestones and partner execution.
- Hosted-software migration may pressure reported revenue and require sustained customer adoption.
- No reliable post-earnings analyst target changes, estimate revisions, or consensus-surprise data were available.
- Q2 profitability was materially affected by the Ajax-related investment gain and may not represent recurring earnings power.
- The CEO reported open-market share sales in April, although the filings also showed option exercises. [#SEC-FORM4-2026-04-17]
Peers
No peer data
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-08-08